Rallybio Corp
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
RLYB$15.76+0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets
| (in thousands, except share and per share amounts) | MARCH 31,2025 | DECEMBER 31,2024 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $14,779 | $13,903 |
| Marketable securities | 39,716 | 51,608 |
| Prepaid expenses and other current assets | 2,886 | 2,330 |
| Total current assets | 57,381 | 67,841 |
| Property and equipment, net | 87 | 115 |
| Operating lease right-of-use assets | 102 | 152 |
| Investment in joint venture | 413 | — |
| Total assets | $57,983 | $68,108 |
| Liabilities and stockholders' equity | ||
| Current liabilities: | ||
| Accounts payable | $400 | $278 |
| Accrued expenses | 2,546 | 4,962 |
| Operating lease liabilities | 116 | 154 |
| Deferred revenue | 848 | 848 |
| Total current liabilities | 3,910 | 6,242 |
| Deferred revenue, noncurrent | — | 212 |
| Total liabilities | 3,910 | 6,454 |
| Commitments and contingencies (Note 7) | ||
| Stockholders' equity | ||
| Common stock, $0.0001 par value per share; 200,000,000 shares authorized as of March 31, 2025 and December 31, 2024; and 41,612,039 and 41,510,163 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | 4 | 4 |
| Preferred stock, $0.0001 par value per share; 50,000,000 shares authorized as of March 31, 2025 and December 31, 2024; no shares issued or outstanding as of March 31, 2025 and December 31, 2024 | — | — |
| Additional paid-in capital | 356,481 | 354,602 |
| Accumulated other comprehensive gain | 47 | 68 |
| Accumulated deficit | (302,459) | (293,020) |
| Total stockholders' equity | 54,073 | 61,654 |
| Total liabilities and stockholders' equity | $57,983 | $68,108 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.